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Abstract
The EphA2 receptor tyrosine kinase has been shown to
be over-expressed in cancer and amonoclonal antibody
(mAb) that activates and down-modulates EphA2 was
reported to inhibit the growth of human breast and
lung tumor xenografts innudemice.Reductionof EphA2
levels by treatment with anti-EphA2 siRNA also inhib-
ited tumor growth, suggesting that the anti-tumor effects
of these agents are mediated by decreasing the levels of
EphA2. As these studies employed human tumor xeno-
graft models in nude mice with reagents whose cross-
reactivity with murine EphA2 is unknown, we generated
a mAb (Ab20) that preferentially binds, activates, and
induces the degradation of murine EphA2. Treatment of
established murine CT26 colorectal tumors with Ab20
reduced EphA2 protein levels tof12% of control tumor
levels, yet had no effect on tumor growth. CT26 tumor
cell colonization of the lung was also not affected by
Ab20 administration despite having barely detectable
levels of EphA2. We also generated and tested a potent
agonistic mAb against human EphA2 (1G9-H7). No inhi-
bition of humanMDA-231 breast tumor xenograft growth
was observed despite evidence for >85% reduction of
EphA2 protein levels in the tumors. These results sug-
gest that molecular characteristics of the tumors in ad-
dition to EphA2 over-expression may be important for
predicting responsiveness to EphA2-directed therapies.
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Introduction
EphA2 is one of 16 related receptor tyrosine kinases that are
activated by membrane-associated ligands known as eph-
rins (for review, see Refs. [1,2]). EphA2 protein levels have
been reported to be elevated in breast cancer [3], prostate
cancer [4], ovarian cancer [5], non–small cell lung cancer
(NSCLC) [6], gastric cancer [7], squamous cervical carcinoma
(SCC) [8], and esophageal squamous cell carcinoma (ESCC)
[9], as well as in vertical growth-phase melanomas [10]. EphA2
is proposed to be a potential target for cancer therapy, as
overexpression of EphA2 is significantly correlated with shorter
overall survival in NSCLC [6], ESCC [9], SCC [8], and ovarian
cancer [5], and with cancer progression and metastasis in
colorectal cancer [11].
Although EphA2 protein levels are elevated in tumors, the
EphA2 phosphorylation state in MDA-MB-231 breast cancer
cells was found to be lower than that in ‘‘normal’’ MCF10A
mammary epithelial cells, suggesting that reduced signaling
through this pathway occurs in tumor cells that overexpress
EphA2 [12]. Because cell–cell interaction is necessary to
trigger ligand-dependent EphA2 phosphorylation, it was pro-
posed that tumor cells either do not express appropriate
ligands (i.e., ephrinA1–A5) or cannot form contacts that enable
productive ephrinA–EphA2 interaction. Subsequent studies
tested the hypothesis that exposure to ligand mimetics could
inhibit tumor-associated phenotypes. Thus, dimerization of
the ephrinA1 ligand by fusion to the Fc portion of human IgG1
[i.e., ephrinA1-Fc (EA1-Fc)] was shown to trigger rapid EphA2
phosphorylation and receptor downmodulation inMDA-MB-231
breast [12,13] and PC-3 prostate [14] cancer cells. EA1-Fc
treatment of PC-3 cells inhibited cell spreading on fibronectin,
caused dephosphorylation/inactivation of focal adhesion ki-
nase, and decreased clonal cell growth [14,15]. Monoclo-
nal antibodies (mAbs) that induced EphA2 phosphorylation
in MDA-MB-231 breast cancer cells—but not those lacking
agonist activity—reduced cell piling in monolayer culture, in-
hibited anchorage-independent growth, and blocked invasive
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outgrowth in Matrigel [13]. The agonistic mAb EA2 was also
shown to inhibit the growth of MDA-MB-231 and A549 lung
tumor xenografts in nude mice [16]. In such study, the tumor
growth–inhibitory effects of antibody treatmentwere attributed
to decreased EphA2 protein levels induced by receptor acti-
vation and degradation.
Reduction of EphA2 levels through treatment with anti-
EphA2 antisense oligonucleotides (ASO) or siRNA has also
been reported to inhibit in vitro tumor cell phenotypes. The
invasive behavior of uveal melanoma cells, resembling vas-
culogenic mimicry [17] and MDA-MB-231 growth in soft agar
[13], was inhibited by ASO-mediated knockdown of EphA2
expression. Pancreatic tumor cell invasion, migration, and
in vivo tumor formation [18] were suppressed by siRNA that
targeted EphA2. The observed effectiveness of both EphA2
agonists and ASO/siRNA suggested that antitumor effects
were mediated by decreasing the levels of EphA2.
In addition to roles in tumor cell invasion, migration, ad-
hesion, and survival, EphA2 has also been reported to be
important in tumor angiogenesis [19] and in immune (i.e.,
dendritic) cell function [20,21]. Indeed, one of the EphA2
ligands, ephrinA1, was originally identified as an angiogenic
factor produced by tumor necrosis factor a–stimulated en-
dothelial cells [22]. It is unclear whether potential contribution
to the growth of EphA2 activity from the murine host (i.e.,
endothelial, stromal, and immune cells) was impacted in the
abovementioned studies. Those studies were performed
with human tumor xenografts implanted in nude mice, and
no data regarding cross-reactivity for murine EphA2 of the
anti-EphA2 siRNA or agonistic antibodies were reported. We
have therefore generated mAbs that preferentially target
the murine EphA2 protein (Ab20) to determine the efficacy
of anti-EphA2 therapy in a syngeneic tumor model, where
both tumor and host cells are of murine origin. We have also
generated an antibody that targets the human EphA2 re-
ceptor (1G9-H7). Both of these antibodies are potent EphA2
agonists and elicit the rapid phosphorylation and down-
modulation of the receptor at concentrations similar to those
of the dimeric ephrinA1 ligand. However, these antibodies
did not impact the growth of either the murine syngeneic
tumor or the human tumor xenograft despite causing sub-
stantial reduction in the levels of EphA2 protein.
Materials and Methods
Cell Lines and Culture Conditions
Human breast cancer (MDA-MB-134V1 and MCF7), mu-
rine colon cancer (CT-26), murine Lewis lung carcinoma
(LLC1), and human HEK293 and HEK293-EBNA (293E) cell
lineswere obtained from theAmericanTypeCultureCollection
(ATCC; Manassas, VA) and were cultured under conditions
recommended by the supplier. Murine BWZ.36 thymoma
(referred to as BWZ) cells are a derivative of ab BW5147
[23] and are kind gifts from Prof. Nilabh Shastri. MDA-MB-231
breast cancer cells (ATCC) were subcutaneously implanted
in nude BALB/c mice, and one of the rapidly growing tumors
was cultured in vitro to obtain MDA-231MT-1, which was
used in the studies described in this publication (referred to
as MDA-231). No significant differences were noted between
the in vivo–selected cells and the parental population in in vitro
characteristics, such as migration, invasion, or gene expres-
sion profiles as previously reported [24]. MDA-231 cells were
cultured in alpha-modified minimal essential medium supple-
mented with 2.0 mM glutamine, 0.1 mM minimal essential
amino acids, 1.0 mM sodium pyruvate (all from Invitrogen,
Carlsbad, CA), 1.0 mg/ml insulin (Sigma, St. Louis, MO), and
10% fetal calf serum (FCS; SeraCare Life Sciences, Inc.,
Oceanside, CA).
HEK293 cells were transfected using Lipofectamine 2000
(Invitrogen) with pcDNA6-EphA2 [pcDNA6 (Invitrogen) en-
coding the full-length sequence–confirmed EphA2 protein]
and were selected with BlasticidinS (Invitrogen). The 293-
EphA2 cells used in this study were the progeny of a single
cell clone, whose expression of EphA2 was verified by
immunoblot, fluorescence-activated cell sorter (FACS), and
immunocytochemical analyses.
Animals
Eight- to 10-week-old female nude mice (nu/nu) (Simon-
sen, Gilroy, CA) were used for the orthotopic MDA-231 human
tumor xenograft model, and 6- to 8-week-old female BALB/c
mice (Charles River, Hollister, CA) were used for the CT26
syngeneic tumor model. Mice were subcutaneously implanted
with an electronic identification transponder (Biomedic Data
Systems, Seaford, DE) and were housed in facilities approved
by the American Association for Accreditation of Laboratory
Animal Care. The Berlex Biosciences Animal Care and Use
Committee approved all experimental designs. For use in
animal experiments, all antibodies were confirmed to have
endotoxin levels of less than 20 EU per daily dose (Nelson
Laboratories, Inc., Salt Lake City, UT).
Recombinant Proteins and Antibody Reagents
Human EphA1-Fc, mEphA2-Fc, mEphA3-Fc, mEphA4-
Fc, rEphA5-Fc, mEphA6-Fc, mEphA7-Fc, mEphA8-Fc, and
mEA1-Fc were purchased from R&D Systems (Minneapolis,
MN), and human IgG Fc fragment was purchased from
Rockland Immunochemicals, Inc. (Gilbertsville, PA). Human
EphA2-ECD was generated by transfecting 293E cells with
pCEP4 encoding an N-terminal IgK signal sequence and a
C-terminal V5/His6–tagged EphA2-ECD (amino acid se-
quences 23–524). Following growth in Gibco P6 media
(Invitrogen), cells were pelleted and 9L cells of a supernatant
containing EphA2 were processed. The protein was purified
using Ni–NTA agarose (Qiagen, Hilden, Germany) and sub-
sequent gel filtration using Superdex200. The protein was
shown to have greater than 90% purity by analytic size
exclusion chromatography and sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis (SDS-PAGE).
Anti-EphA2 antibody C-20 and horseradish peroxidase
(HRP)–conjugatedanti-rabbit andanti-mouse IgG (SantaCruz
Biotechnology, Santa Cruz, CA) and anti–b-actin antibody
clone AC-40 (Sigma-Aldrich, St. Louis, MO) were used in this
study. The anti–human EphA2 antibody 355A93 (mAb A93,
IgG2a, and kappa) used in immunoprecipitation applications
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was generated by the immunization of Swiss/Webster mice
with pcDNA6-EphA2 and by further boosting with purified
EphA2-ECD. Spleen and lymph nodes were harvested to
create hybridomas (Strategic Biosolutions, Newark, DE). The
antibody used to detect phosphotyrosine (4G10) was pur-
chased fromUpstate Biotechnology (Waltham,MA); Alexa488
or Alexa546 goat anti-human and anti-mouse IgG were from
Molecular Probes (Eugene, OR). Isotype control IgG2b and
IgG3murine antibodies were purchased fromRockland Immu-
nochemicals, Inc., and purified by anion exchange chroma-
tography (Strong Basic Anion Exchanger Q15X; Sartorius AG,
Goettingen, Germany).
Generation of Murine EphA2-Selective Antibodies
Thehuman combinatorial antibody libraryHuCALGold Fab
library (Morphosys, Martinsried, Germany), which was gener-
ated by transferring heavy- and light-chain variable regions
from a previously constructed single-chain Fv library [25], was
used for panning experiments with the mEphA2-Fc antigen.
The HuCAL Gold Fab display library contains 2.1  1010 dif-
ferent human antibody fragments. The panning process was
performed as previously described [26,27]. Briefly, wells of a
96-well plate were coatedwith 300 ml of recombinant mEphA2-
Fc [50 mg/ml in phosphate-buffered saline (PBS); R&D Sys-
tems], and three rounds of panning were completed. After
several washings, phages were eluted with dithiothreitol and
amplified, and Fab-encoding fragments from the second and
third rounds of panning were excised as a pool and cloned into
the pMorph_x9_dHLX_MS format for screening. The dHLX
format enables dimerization of Fabs and is based on a human-
derived self-assembling polypeptide derived from the tetrame-
rization domain of the human transcription factor p53 [28].
FV-negative TG1 was transformed with Fab-dHLX clones, and
744 single clones were screened in a 96-well plate format.
Periplasmic extracts from positive unique clones based on
DNA sequence analysis were then prepared as previously
described [26] and analyzed by direct enzyme-linked immu-
nosorbent assay (ELISA) on recombinant mEphA2-Fc by
standard methods [27]. Positive Fab-HLX was purified and
tested for binding to EphA2-expressing cells in FACS analy-
ses. Confirmed positives were converted to IgG3 format by
subcloning into the pMorph_h/m_IgG3_1 and pMorph_h/
m_IgGn_ or pMorph_h/m_IgG E_ expression vectors and
were subsequently expressed in CHO cells. These expression
vectors yielded mouse chimeric antibodies with murine con-
stant regions and human variable regions.
Generation of Human EphA2 Antibodies
Human lung carcinoma cell lines with different invasive
and metastatic capabilities (CL1-0 and its sublines CL1-1 to
CL1-5) have been described [29]. mAbs against human lung
cancer cells were produced by immunizing BALB/c mice with
highly metastatic CL1-5 cells and by selecting antibodies that
preferentially bound CL1-5 cells compared with CL1-0 cells
[30]. mAb 1G9-H7 was found to bind EphA2 by the immuno-
precipitation of solubilized CL1-5 cell membrane proteins fol-
lowed by in-gel digestion and mass spectrometric analysis,
as described [31].
FACS Binding Analyses
Cells were cultured to approximately 80% confluency,
detachedwith Versene orCell Dissociation Buffer (Invitrogen),
centrifuged, and resuspended in ice-cold PBS. Cells [1 
105 cells/well in 96-well round-bottom Pro-Bind Assay plates
Recton Dickinson Labware (Falcon, Franklin Lakes, NJ)
analyzed using PCA-96 FACS instrument (Guava, Hayward,
CA), or 1  106/cells/1.5-ml microtube analyzed using
FACSCalibur (BD Biosciences, Franklin Lakes, NJ)] were
centrifuged and incubated with 200 ml of primary antibody
(diluted in PBS at concentrations indicated in figure leg-
ends) for 1 hour at 4jC, with constant agitation. Following
three washes with ice-cold PBS, cells were resuspended in
200 ml of either anti-mouse or anti-human IgG Alexa546
(1:500 in PBS for PCA-96 analysis) or anti-mouse or anti-
human IgGAlexa488 (1:500 inPBS for FACSCalibur analysis)
and incubated for 30 minutes at 4jC, with constant agitation.
Following three washes with ice-cold PBS, cells were resus-
pended in 200 ml of PBS containing 2 mg/ml 7AAD (Molecular
Probes) for PCA-96 analysis, or in 2 mg/ml propidium iodide
(Molecular Probes) for FACSCalibur analysis. Samples were
analyzed by the 96-well PCA-96 FACS instrument using the
preset ‘‘Guava Express’’ software, or by the FACSCalibur
machine using the preset ‘‘Cell Quest’’ software.
EphA2 Activation Studies
MDA-231 cells (6  104 cells/well) or CT26 cells (2  105
cells/well) were seeded in a six-well plate. Two days later, the
medium was removed and replaced with FBS-free medium
(for CT26) or fresh medium (for MDA-231), including EA1-Fc
or antibodies, at the concentrations indicated in the figure
legends. Cells were incubated at 37jC for the indicated
times, rinsed once with cold PBS, and lysed in RIPA-PP
[modified RIPA buffer (0.5% deoxycholate, 0.1% SDS, 1%
Triton X-100, and 5mMEDTA in PBS, pH 8.0), supplemented
with protease inhibitors (Complete Tablet EDTA-free; Roche
Diagnostics GmbH, Mannheim, Germany) and 5 mM sodium
vanadate (Aldrich Chem. Co., Milwaukee, WI)]. Samples
were sonicated, protein concentration was determined by
BCA (Pierce, Rockford IL), and EphA2 was immunoprecipi-
tated overnight at 4jC in a final volume of 600 ml. For MDA-
231, 500 mg of total protein was incubated with 5 mg of A93
anti-EphA2 antibody; for CT26, 450 mg of protein with 6 mg
of anti-EphA2 (C-20) antibody and 30 ml of protein A (for C-20)
or protein G (for A93) beads (20 mg/ml; Amersham Biosci-
ences Corp., Piscataway, NJ) was diluted in RIPA-PP buffer.
Beads were washed three times with HNTG (25 mM HEPES,
pH 7.4, 150 mM NaCl, 1% Triton X-100, and 5% glycerol)
buffer, eluted with hot SDS-PAGE sample buffer, and subjected
to immunolot analysis.
Western Blot Analysis
Approximately 80% confluent 293, 293EphA2, BWZ,
CT26, and LLC1 cells were lysed in RIPA-PP buffer, soni-
cated, and denatured by boiling in SDS-PAGE sample buffer
(Invitrogen) with 10% Bond-Breaker TCEP Solution (Pierce),
and the components were resolved by electrophoresis in
4% to 12% or in 4% to 20% Tris–glycine gels (Cambrex
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BioScience Rockland, Inc., Rockland, ME). Proteins were
transferred to a 0.2-mm nitrocellulose membrane (Invitrogen)
and blocked with 5% milk powder in StartingBlock (PBS
formulation; Pierce) with 0.1% Tween-20 (Sigma) for
1 hour at room temperature (RT), with constant agitation.
Primary antibodies [anti-EphA2 (C-20; 0.05 mg/ml), anti-
phosphotyrosine (4G10; 0.01 mg/ml), and anti –b-actin
(0.05 mg/ml)] were diluted in blocking buffer and incubated
for 1 hour at RT, with constant agitation. After washing with
PBST (PBS with 0.1% Tween-20), the blots were incubated
with either anti– rabbit IgG–HRP (1:5000) or anti–mouse
IgG–HRP (1:5000) in blocking buffer for 1 hour at RT. Blots
were washed with PBST, rinsed once with distilled water, and
processed for the detection of HRP by incubating with Super-
Signal West Pico (Pierce). Where indicated, EphA2 levels were
determinedbyscanningdensitometry using theGelDocsystem
(Bio-Rad, Hercules, CA). To verify equivalent sample loading,
the blots were stripped and reprobed for b-actin.
CT26 Invasion Assay
CT26 cells were cultured to approximately 80% confluency,
detached with Cell Dissociate Buffer, centrifuged, and resus-
pended in growth medium without FBS. Cells were incu-
bated at RTwith mIgG, Ab20, Fc, or EA1-Fc (1 or 5 mg/ml) for
30 minutes before layering 2  105 cells/500 ml in triplicate
onto a rehydrated Matrigel-coated filter on the top chamber
of a Biocoat Tumor Invasion System 24-Multiwell Insert Plate
(BectonDickinson, Bedford, MA). A total of 750 ml of basal me-
dium containing 5% FCS was added to the bottom chamber,
and the plate was incubated at 37jC in a 5% CO2 incubator
for 19 hours. Cells at the bottom of the filter were fixed with
Diff-Quick (Dade Behring, Inc., Dudingen, Switzerland) for
2 minutes and stained with Syto 13 (Molecular Probes) for
30 minutes at 37jC. The fluorescence intensity of invaded
cells was measured with a Victor Fluorometer (Perkin-Elmer,
Boston, MA) and corrected by subtracting the fluorescence
measurement from chambers where no cells were added.
In Vivo Efficacy Studies
MDA-231 tumor xenografts MDA-231 cells [2  106 cells/
mouse mixed 1:1 with Matrigel (BD Biosciences, Bedford,
MA) in a volume of 40 ml] were injected into the left inguinal
mammary fat pad of female athymic mice under light isoflur-
ane anesthesia. The progress of tumor growth was measured
with calipers in two perpendicular directions and calculated
using the formula V =WWL(0.5), where V = volume,W = the
shortest diameter, and L = the longest diameter. Three weeks
after cell inoculation (tumors, 65–150mm3), mice were sorted
into groups of 12 and treatment was initiated. Mice were in-
jected intraperitoneally every second or third day with 125 mg
(in 125 ml) of either 1G9-H7, isotype control antibody IgG2b, or
PBS. One day after the last antibody dose, mice were eutha-
nized, and tumors were excised, weighed, and snap-frozen in
liquid nitrogen.
CT26 syngeneic tumors CT26 cells (1  106 cells/mouse
in 100 ml of PBS) were implanted subcutaneously into the
dorsal flank of female BALB/c mice whose fur was shaved
and depilated with Veet (Reckitt Benckiser, Inc., Wayne NJ).
Tumor volumewas estimated by caliper measurements twice
aweek.Oneweekafter cell inoculation (tumors, 50–100mm3)
and every second or third day thereafter, mice (n = 20/group)
were treated intraperitoneally with 125 mg (in 125 ml) of either
Ab20 or control IgG3 or antibody diluent (330 mM sodium ace-
tate and 150 mMNaCl, pH 5.5) for a total of seven doses. One
day after the final dose, mice were euthanized, and tumors
were excised, weighed, and snap-frozen in liquid nitrogen.
CT26 lung colonization CT26 cells (5  105 cells/mouse in
100 ml of calcium/magnesium-free PBS containing 10 mM
glucose) were injected in the lateral tail vein of BALB/c mice.
Three hours before intravenous cell inoculation and every
second or third day thereafter, mice (n = 20/group) were treated
intraperitoneally with 125 mg (in 125 ml) of either Ab20 or control
IgG3. One set of age-matched mice was used for the de-
termination of normal lung weight. Two days after the final
antibody dose, all mice were euthanized by CO2 asphyxiation,
and the lungs were carefully dissected, weighed, and snap-
frozen in liquid nitrogen or fixed in 4% paraformaldehyde in 3%
sucrose buffer. Tumor burden was estimated by subtracting
the normal lung weights of mice that received no CT26 cells
from the lungweights of animals injected with CT26 tumor cells.
Tumor Tissue Extraction
Frozen tumors were fragmented with the aid of a Bess-
man tissue pulverizor (Spectrum Laboratories, Inc., Rancho
Dominguez,CA) and transferred toprecooled cryovials in a dry
ice–ethanol bath. Approximately 100 to 300 mg of tumor was
extracted in 1 ml of RIPA-PP buffer by adding two 1/4-in.
ceramic beads and garnet sand (BIO 101, Inc., Carlsbad, CA)
and by shaking the vials in the Fast Prep reciprocal shaker
(Q-biogen, Irvine, CA) for 30 seconds at full speed in a cold
room. The samples were centrifuged for 2 minutes at 15,000g,
and the process was repeated. The supernatant was briefly
sonicated, centrifuged for 5 minutes to clarify the lysate,
quickly frozen, and stored at 80jC. For preparation of ex-
tracts from tumor-bearing lungs, the tissue was weighed and
10-fold excess RIPA-PP buffer was added before homogeniz-
ing with an Omni mixer (Omni International, London, UK). A
total of 100 ml of this crude homogenate was further extracted
and processed using the Fast Prep protocol described above.
Statistical Analysis
Statistical analyses for in vivo tumor growth studies were
performed with JMP 5.0 (SAS Institute, Inc., Cary, NC) using
the Kruskal-Wallis test and the Wilcoxon nonparametric
(Mann-Whitney U ) analysis. Results from in vitro invasion
studies were analyzed by an ANOVA unpaired test. P < .05
was considered significant.
Results
Generation of Antibodies against Murine EphA2
The HuCAL Gold Fab phage display library was screened
for Fab antibody fragments that bound to the murine EphA2-
Agonistic EphA2 mAbs Do Not Inhibit Tumor Growths Kiewlich et al. 21
Neoplasia . Vol. 8, No. 1, 2006
ECD fused to the human IgG1 Fc (i.e., mEphA2-Fc). A total
of 134 mEphA2-binding Fab clones was identified, and a
diversity of 21 was determined after the comparison of
heavy-chain sequences. Following additional screening
analyses, Fab antibody fragments were converted to the
IgG3 format by subcloning, expressed in CHO cells, and the
antibodies were purified.
The antibodies identified by binding to mEphA2-Fc were
tested by FACS-based analyses for their ability to recognize
native EphA2, which is highly expressed by murine CT26
colorectal and LLC1 cells (Figure 1A). The binding of one of
these antibodies (Ab20) to CT26 cells—but not to BWZ cells,
which do not express EphA2—is shown in Figure 1B. Al-
though several antibodies bound to cell surface EphA2
as measured by mean fluorescence intensity, only Ab20
bound with an affinity similar to that of EA1-Fc (Figure 1C).
The EC50 for Ab20 binding was 1.2 to 1.7 nM compared to
0.8 to 2.1 nM for EA1-Fc. Maximal binding was observed at
antibody concentrations of 1 to 2 mg/ml (6–13 nM) compared
with 0.5 to 1 mg/ml (4.5–9 nM) for EA1-Fc. Ab20 did not sig-
nificantly interact with human EphA2 (hEphA2) on MDA-231
breast cancer cells (Figure 1D) or on 293 cells transfected
with hEphA2 (data not shown), even though these human
cell lines express similar or greater levels of EphA2 than
those detected in CT26 and LLC1 (Figure 1A). These data
suggest that Ab20 specifically recognizes murine—but not
human—EphA2. This conclusion is supported by results
from competitive binding studies, where mEphA2-Fc—but
not hEphA2-ECD—competed for the binding of Ab20 to
CT26 tumor cells (Figure 1E ). None of the other EphA
receptor–Fc fusions (murine EphA2, EphA3, EphA4, EphA6,
EphA7, EphA8; rat EphA5; or human EphA1) interfered with
Figure 1. EphA2 expression and FACS binding of Ab20 to cell surface EphA2 in murine and human cells. (A) Western blot analysis of total cell extracts (30 g
protein/lane) from indicated cell lines. EphA2 was detected with the C-20 antibody. Molecular weight standards (kDa) are indicated on the side. (B) CT26 or BWZ
cells were incubated with 5 g/ml mIgG (solid line) or Ab20 (dashed line) for 1 hour at 4jC, labeled with anti-mouse IgG Alexa488, and analyzed by FACS.
Histograms of fluorescence intensity (FITC) versus cell number (counts) are shown. (C) CT26 or LLC1 cells were incubated with indicated concentrations of EA1-
Fc (triangles) or Ab20 (circles) and treated as described in (B). The mean fluorescence for binding at each concentration is graphically shown. The average EC50
for Ab20 binding (n = 3) to CT26 is 1.94 ± 0.24 nM and to LLC1 is 1.52 ± 0.32 nM. EA1-Fc EC50 to CT26 is 2.1 nM and to LLC1 is 0.83 nM. (D) Human MDA-231 cell
binding of indicated antibodies (5 g/ml) or EA1-Fc (0.5 g/ml) was measured as described in (B). (E) CT26 cells were incubated with Ab20 (1 g/ml) in the
presence of indicated concentrations of mEphA2-Fc or other EphA-Fc (10 g/ml; solid bars). The binding of mIgG (1 g/ml) or mEphA2-Fc (10 g/ml) is
represented by open bars. Representative data from at least two independent experiments are shown.
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the binding of Ab20 to CT26 cells, suggesting that Ab20 is se-
lective for murine EphA2.
Ab20 Is a Potent Agonist of Murine EphA2
The EphA2 agonistic potential of Ab20 was assayed by
measuringEphA2autophosphorylation inCT26 cells following
30minutes of incubation with the antibody. EphA2 phosphory-
lation in response to Ab20 increased in a dose-dependent
manner to levels comparable to those observed with maxi-
mally effective concentrations of EA1-Fc (Figure 2A). The
EC50 values for EA1-Fc and Ab20 were also very similar at
f0.25 to 0.5 mg/ml (2–5 nM). The kinetics of phosphorylation
elicited by Ab20 was also quite similar to that for EA1-Fc
(Figure 2B), with maximal EphA2 phosphorylation observed
within 15 minutes of incubation in both CT26 and LLC1 cells
(data not shown). EA1-Fc and Ab20 also induced receptor
degradation with similar kinetics (Figure 2C), rapidly reducing
EphA2 protein levels within the first 2 hours of treatment and
achieving f80% reduction by 8 hours. Decreased levels of
EphA2 were maintained for at least 48 hours.
Ab20 Inhibits CT26 Tumor Cell Invasion
The ability of Ab20 to interfere with CT26 tumor cell inva-
sion through a reconstituted basement membrane (i.e., Matri-
gel) was evaluated using a modified Boyden chamber assay.
Ab20 significantly reduced invasion by approximately two-fold
at a concentration of 5 mg/ml (33 nM), whereas weaker inhi-
bition, although not statistically significant, was observed with
EA1-Fc treatment (Figure 3). No effect was observed with
mIgG3 or Fc controls. Ab20 caused no antiproliferative effects
on CT26 growth in monolayer culture (data not shown).
Ab20 Treatment Reduces EphA2 Protein Levels in CT26
Tumor Xenografts But Does Not Affect Primary Tumor
Growth or Lung Colony Formation
Given the strong agonistic activity of Ab20 in eliciting
EphA2 phosphorylation and degradation in CT26 tumor
cells, the effectiveness of Ab20 in controlling CT26 tumori-
genicity in BALB/c mice was evaluated. Antibody adminis-
tration was initiated 1 week after tumor cell implantation,
when tumors were f50 to 100 mm3, and continued on a
thrice-weekly injection schedule until mice were sacrificed
f24 hours after the final injection on day 22. No change in
tumor growth kinetics was observed over the course of this
treatment (Figure 4A). The histopathology and weight of the
tumors from treated and untreated mice were not different
(data not shown). It is also noteworthy that there were no
Figure 2. Effect of Ab20 on the phosphorylation and degradation of EphA2 in CT26 cells. (A) CT26 cells were incubated with Ab20 or EA1-Fc at 37jC with indicated
concentrations for 30minutes or (B) with 1 g/ml Ab20 or 0.5 g/ml EA1-Fc for indicated times. Cell extracts were prepared in RIPA-PP buffer, and 450 g of protein was
immunoprecipitatedwith anti-EphA2polyclonal antibody (C-20).Western blotswere probedwith anti-phosphotyrosine (4G10) andanti-EphA2 (C-20), respectively. Arrows
indicate tyrosine-phosphorylated EphA2. (C) CT26 cells were treated with indicated concentrations of EA1-Fc or Ab20 for indicated times, and cell extracts (20 g/lane)
were evaluated by Western blot analysis for EphA2 and -actin levels. Data shown are representative of at least two independent experiments.
Figure 3. Effect of Ab20 on CT26 tumor cell invasion. CT26 cells (2  105)
were preincubated with Ab20 or EA1-Fc at RT for 30 minutes and plated onto
Matrigel-coated membranes in a modified Boyden chamber. Cell invasion was
measured after 19 hours of treatment. Data are the normalized and averaged
results from four independent experiments. *Statistically significant at P < .05.
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apparent adverse effects of administering Ab20, as recorded
by body weight measurements (data not shown).
To rule out the possibility that the concentrations of the
Ab20 reaching the tumor were insufficient to induce phosphory-
lation and degradation, EphA2 levels were measured in all of
the tumors. In every tumor excised from mice that received
Ab20 treatment—but not in those from control mIgG3– or
vehicle-treated mice—EphA2 levels were markedly reduced
(Figure 4B). The mean reduction was f85%, clearly demon-
strating that the Ab20 antibody was effective in reaching
tumormass and inducing the degradation of the EphA2 protein.
However, it was theoretically possible that Ab20 was in-
effective in the early days of treatment and therefore could
not affect these rapidly growing tumors. Such a delayed ef-
fectiveness might not be observed in tumors analyzed after
2 weeks of chronic antibody treatment. In a separate study,
CT26 tumor–bearing mice were given a single injection of
Ab20 and tumors were harvested 24 hours later. In this
case, in EphA2 protein levels were reduced 80% to 85%
(Figure 4C) and were therefore comparable to those observed
following chronic dosing with the antibody, demonstrating
the effectiveness of Ab20 in eliciting EphA2 degradation soon
after treatment.
Because the in vitro efficacy data supported a role for
EphA2 in the invasion of CT26 tumor cells, the ability of Ab20
to impact metastatic behavior, as measured by CT26 cell
seeding and growth in the lung following tail vein injection,
was also assessed. Fifteen days after injection, the CT26
tumor nodules accounted for nearly 50% of the total weight
of the lung in the mIgG3- and Ab20-treated mice (Figure 5A,
left side). Histopathological examination confirmed that a
large percentage of the lung parenchyma was effaced by
multifocal to coalescing nodular neoplasms (data not shown).
No significant effect on tumor burden was observed in mice
treated with Ab20 (Figure 5A, right side), even though the
antibodies were administered 3 hours prior to tumor cell in-
oculation. In addition, no effects of Ab20 administration on
animal body weight were observed (data not shown).
The pharmacodynamic activity of Ab20 was verified by
measuring EphA2 levels in the CT26 tumor nodules. Extracts
prepared from lungs of treated and untreated mice were
compared with those from mice that were not injected with
CT26 tumor cells. In agreement with the reported expression
of EphA2 mRNA in normal rat lung tissues [32], a low level
of EphA2 protein was detectable in lungs from naı¨ve mice
(Figure 5B). The EphA2 levels detected in the lungs from
mice injected with CT26 tumor cells were very high, as
expected, due to the high expression of EphA2 in CT26
tumors. Importantly, tumors from Ab20-treated mice
contained nearly undetectable levels of EphA2, consistent
with an Ab20-mediated degradation of the protein.
Characterization of mAbs against hEphA2
Antibodies that recognize hEphA2 were generated
through a cellular immunization strategy in a search for anti-
gens that were overexpressed in highly metastatic human
lung tumor cells (CL1-5) [30]. hEphA2 was identified as
the antigen for the 1G9-H7 antibody following its immuno-
precipitation from CL1-5 cells and liquid chromatography–
mass spectrometry sequencing analysis. The specificity of
1G9-H7 for EphA2 was confirmed by its ability to only bind
EphA2-expressing cells in FACS analyses (Figure 6A). The
mean fluorescence intensity of 1G9-H7 binding to MDA-231,
which expresses very high levels of EphA2 (Figure 1A),
Figure 4. Effect of Ab20 administration on subcutaneous CT26 tumor growth and EphA2 levels. (A) Mice bearing subcutaneous CT26 tumors (50–100 mm3;
n = 20/group) were treated with vehicle, mIgG3, or Ab20 (125 g/dose) according to the schedule shown (arrows). Mean tumor volumes are graphically re-
presented. The corresponding tumor weights (g) were as follows: vehicle, 1.49 ± 0.22; mIgG3, 1.35 ± 0.19; and Ab20, 1.77 ± 0.21. Error bars, SEM. (B) Western
blot analysis of extracts (25 g of protein) from subcutaneous CT26 tumors excised 1 day after the final treatment. EphA2 was detected with anti-EphA2 antibody
C-20, and the data for half of the tumors from each group (vehicle, V1–V9; mIgG3, C1–C10; and Ab20, A1–A10) are shown. Similar results were obtained with the
remaining tumors. Average (± SD) EphA2 levels determined by densitometric scanning of the blots were as follows: vehicle, 9710 ± 1272; mIgG3, 9674 ± 204; and
Ab20, 1413 ± 979 arbitrary units. (C) CT26 tumor lysates from mice treated for 24 hours with mIgG3 (C1 and C2) or Ab20 (A1 and A2) were analyzed as in (B).
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was much greater than that for MCF7 (with very low levels
detected on long exposure of the blot; data not shown) and
MDA-MB-134VI (with undetectable levels). A dose-depen-
dent binding of 1G9-H7 to 293 cells stably transfected with
hEphA2 (293-EphA2)—but no binding to the parental 293
cells—was observed (Figure 6B). The EC50 for 1G9-H7
binding to 293-EphA2 cells was 1.8 nM, and similar data were
obtained for binding to EphA2 on MDA-231 cells (data not
shown). EA1-Fc binds to MDA-231 and 293-EphA2 cells with
similar potency (data not shown).
The potential species specificity of 1G9-H7was addressed
by measuring binding to mEphA2 on CT26 and LLC1 tumor
cells. 1G9-H7 bound very well to hEphA2 on MDA-231 and
293-EphA2 cells, but weakly (or not at all) bound to mEphA2
on CT26 or LLC1 tumor cells (Figure 6C). In competitive
binding studies, incubation with excess hEphA2-ECD—but
not mEphA2-Fc—reduced 1G9-H7 binding to MDA-231 cells
(Figure 6D). No competition for binding was observed with
hEphA1 (Figure 6D), which was one of the most closely re-
lated EphA to EphA2 (i.e., 55.9% amino acid similarity in the
extracelluar domain) or with any of the rodent EphAs (data not
shown). These data indicate that 1G9-H7 preferentially binds
human EphA2.
Antibody IG9-H7 Is a Potent Activator of hEphA2
The agonistic activity of 1G9-H7 was measured on MDA-
231 cells in comparison to EA1-Fc following a 10-minute
incubation. The level of EphA2 phosphorylation induced by
1G9-H7 treatment was f40% to 50% of that observed with
EA1-Fc (Figure 7, A and B), but was of similar potency (EC50
f0.25 mg/ml or 1.7 nM; Figure 7A). The kinetics of EphA2
phosphorylation by EA1-Fc and 1G9-H7 was also very similar,
with peak activation at approximately 10 minutes for both
agonists (Figure 7B). Incubation with EA1-Fc or 1G9-H7 for
longer times resulted in receptor degradation to levels that
were barely detectable 8 hours after stimulation (Figure 7C),
with very similar kinetics for the antibody and the dimeric ligand.
1G9-H7 Fails to Inhibit MDA-231 Tumor Growth But
Dramatically Reduces Tumor EphA2 Levels
The antitumor effectiveness of the 1G9-H7 anti-EphA2
agonistic antibody was evaluated in MDA-231 tumor xeno-
grafts orthotopically implanted in the mammary fat pads of nu/
nu mice. Antibody treatment was initiated when the tumors
were 65 to 150 mm3, and intraperitoneal injections were re-
peated thriceweekly over the course of the study until 24 hours
before sacrifice. There was no effect of 1G9-H7 administration
on the growth rate of MDA-231 tumors (Figure 8A). The
histopathology and weight of the tumors from treated and
untreated mice were also not different (data not shown).
The levels of EphA2 protein were measured in extracts
from theexcised tumors. Therewas little variation in theEphA2
levels in the tumors from the PBS and the isotype-matched
IgG2b-treatedmice, but all of the tumors from1G9-H7–treated
mice had significantly lower (83%) levels of EphA2 than the
controls (Figure 8B ). These pharmacodynamic data show that
the 1G9-H7 antibody displayed expected activity in the tumor
but was unable to influence its growth.
Figure 5. Effect of Ab20 treatment on CT26 lung colonization and EphA2 levels. CT26 cells (5  105) were injected into the lateral tail vein of BALB/c mice. Three
hours before intravenous cell inoculation and every second or third day thereafter, mice (n = 20/group) were treated intraperitoneally with 125 g of either Ab20 or
isotype-matched control mIgG3. (A) Left side: Photographic images are shown for a representative lung (corresponding weight also indicated) from each treatment
group at the end of the study. (A) Right side: Average tumor burden [lung weight of CT26-injected mice minus the average weight of lungs from naı¨ve mice (0.129 ±
0.013 g)] is graphically depicted. Error bars, SEM. (B) EphA2 levels in lung tissue extracts (50 g protein/lane) from naı¨ve (L1–L6)– , mIgG3 (C1–C6)– , and Ab20
(A1–A6)– treated CT26-bearing mice were analyzed by immunoblotting for EphA2 and -actin levels.
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Discussion
In this study, we describe the generation and characteriza-
tion of two mAbs that are potent agonists of either the mouse
or the human EphA2 receptor tyrosine kinase. Compara-
tive analyses revealed that the Ab20 (mouse) and 1G9-H7
(human) antibodies are similar to the dimeric EA1-Fc ligand in
their potency and kinetics of stimulating EphA2 phosphoryla-
tion and degradation. However, in spite of their efficiency in
substantially reducingEphA2 levels inmurineCT26 colorectal
tumors and in human MDA-231 breast tumor xenografts,
neither of these antibodies inhibited in vivo tumor growth.
Reported studies with agents that target EphA2 for degra-
dation (i.e., agonistic antibodies and siRNA) were performed
in human tumors that were xenografted onto immunocom-
promised mice. Therefore, the aim of our study was to eval-
uate the activity of an agonistic EphA2-targeting antibody in a
murine syngeneic tumor model where effects on EphA2 func-
tion in both tumor and host cells (i.e., endothelial, stromal, and
immune cells) would be potentially targeted. We selected the
murine CT26 colorectal tumor model for these studies be-
cause these cells express very high levels of EphA2 protein
and form rapidly growing, highly vascularized tumors in mice.
Importantly, a recent study correlated the overexpression of
the EphA2protein in human colorectal carcinomaswith cancer
progression and metastasis [11], thereby providing a clinical
rationale for testing therapeutic antibodies in this indication.
To evaluate the efficacy of an EphA2-targeting antibody in
a murine syngeneic tumor model, we generated an antibody
(Ab20) that specifically recognizes mEphA2 using phage dis-
play technology. The preferential affinity of Ab20 for mEphA2
was demonstrated by binding to EphA2-expressing—but not
EphA2-negative—murine cell lines as well as competitive
binding analyses. Only mEphA2-Fc was a competitive inhib-
itor of Ab20 binding to mEphA2 on cells. hEphA2 ECD, which
shares 90% sequence similarity with the mEphA2 ECD and a
panel of six other rodent EphA ECD–Fc fusion proteins,
which are 50% to 55% homologous to the EphA2 ECD, were
all inactive in this competitive binding assay.
Figure 6. FACS binding of 1G9-H7 to human EphA2-expressing cells. (A) The indicated human breast cancer cells were incubated in the presence and absence
(no addition, secondary Ab only) of 1G9-H7 or normal mouse IgG (2 g/ml) for 1 hour at 4jC. Primary antibody was detected with anti-mouse IgG Alexa546, and
samples were analyzed on a Guava PCA96. The mean fluorescence for each incubation condition is graphically represented. (B) 293 cells (open symbols) and
293-EphA2 cells (solid symbols) were incubated with indicated concentrations of 1G9-H7 (squares) or mIgG (circles), and bound primary antibodies were detected
with mouse IgG-Alexa546 by FACS analysis. Mean fluorescence data points for duplicate samples are graphically represented. Calculated EC50 = 1.8 nM.
(C) Indicated cells were incubated with 2 g/ml mIgG or 1G9-H7, and bound primary antibodies were detected with anti-mouse IgG Alexa488 by FACS analysis.
(D) MDA-231 cells were incubated with 1G9-H7 (2 g/ml) and indicated concentrations of hEphA2-ECD or the various soluble EphA receptor proteins at 25 g/ml
at 4jC for 1 hour. Cell-bound 1G9-H7 was detected with anti-mouse IgG Alexa546 by FACS analysis. Error bars, SD. The murine IgG secondary antibody does not
bind to human Fc (data not shown). Data shown are representative of at least two independent experiments.
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Ab20 showed remarkable similarity to EA1-Fc in its abil-
ity to stimulate EphA2 phosphorylation in CT26 colorectal
carcinoma cells. As expected for a potent agonist, Ab20 also
induced the degradation of EphA2, with time dependency
and efficiency similar to those of EA1-Fc. Surprisingly, intra-
peritoneal administration of Ab20 to mice bearing subcuta-
neously implanted CT26 tumors had no effect on tumor
growth. Yet, the level of EphA2 protein in tumors excised from
every one of the Ab20-treated mice was reduced by f85%
relative to levels in tumors from the isotype-treated controls.
Moreover, a separate study demonstrated that even a 24-hour
treatment with Ab20 was sufficient to substantially reduce
tumor EphA2 levels, suggesting that Ab20 accumulated in
the tumor and displayed expected EphA2 degradation–
Figure 7. Comparison of EphA2 activation by 1G9-H7 and EA1-Fc. (A) MDA-231 cells were incubated with 1G9-H7 or EA1-Fc at indicated concentrations for
10 minutes at 37jC. EphA2 in total cell lysates was immunoprecipitated and analyzed by Western blot analysis using either anti-phosphotyrosine (P-Tyr) or anti-
EphA2 (C-20) antibodies. Fc and mIgG were incubated at 10 g/ml. (B) Western blot analysis of immunoprecipitated extracts prepared at the indicated time points
following stimulation of MDA-231 cells with 1 g/ml EA1-Fc or 1G9-H7. (C) The effect of treatment for the indicated times with Fc, EA1-Fc, mIgG, or 1G9-H7 (5 g/ml)
on EphA2 protein levels was evaluated byWestern blot analysis using anti-EphA2 (C-20) antibody. Equivalent loading was verified by reprobing the blots with an anti –
-actin antibody. Similar results were observed at 0.5 g/ml 1G9-H7. Data shown are representative of at least two independent experiments.
Figure 8. Effect of anti-human EphA2 antibody 1G9-H7 on MDA-231 tumor growth. (A) Mice bearing MDA-231 orthotopically implanted tumors (50–200 mm3;
n = 12/group) were treated with vehicle, mIgG2b, or 1G9-H7 (125 g/dose) according to the schedule shown (arrows). Mean tumor weights (g) were as follows:
vehicle, 1.94 ± 0.36; IgG2b, 2.45 ± 0.28; and 1G9-H7, 2.72 ± 0.52. Error bars, SEM. (B) Western blot analyses of extracts (30 g of total protein) from the MDA-231
tumors excised from vehicle (V1 and V2)– , mIgG2b (C1–C12)– , or 1G9-H7 (G1–G11)– treated mice probed with anti-EphA2 (C-20) and anti –-actin antibodies.
Average (± SD) EphA2 levels determined by densitometric scanning of the blots: control, 1535 ± 296; and 1G9-H7, 268 ± 89.
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promoting activity shortly after administration. Yet, despite
this evidence for the agonistic effects of Ab20 treatment in
the tumors, there was no tumor growth inhibition.
The observed in vitro inhibitory activity of Ab20 in CT26
tumor cell invasion led us to evaluate its effects on the CT26
cell colonization of the lung. In this study, Ab20 was admin-
istered 3 hours prior to the intravenous injection of CT26 cells
to enable the binding and activation of EphA2 before the
extravasation of tumor cells. Again, Ab20 had no antitumor
efficacy, as there was no difference between the tumor bur-
dens in the lungs of Ab20- and IgG3-treated mice. However,
the EphA2 protein levels in the tumor-bearing lungs excised
from Ab20-treated mice were barely detectable, whereas high
levels were found in the tumors from the isotype control–
treated mice. Therefore, despite this evidence for Ab20-
elicited EphA2 degradation in lung tumors, no effect on tumor
growth was observed. Taken together, these results indicate
that high levels of EphA2 are not required for primary CT26
colorectal tumor growth or for tumor cell colonization of the
lung. Thus, CT26 colorectal tumors may not be as sensitive
to EphA2-targeting agents as the human lung (i.e., A549),
breast (i.e., MDA-MB-231), or pancreatic (i.e., MIAPaca-2)
tumor xenografts that were inhibited following treatment with
agonistic anti-EphA2 antibodies [16] or anti-EphA2 siRNA
[18], respectively. It is possible that the residual low levels
of EphA2 in the treated CT26 tumor-bearing mice were
sufficient for sustaining tumor cell growth in vivo, although
the reduction of EphA2 observed in our studies is greater
than that reported in other studies with different tumormodels
(see below).
As this study is the first to employ a syngeneic murine
tumor model for the evaluation of EphA2 agonists, it is also
theoretically possible that inhibitory effects of Ab20 on CT26
tumor cells were opposed by a tumor-promoting activity
mediated through host EphA2-expressing cells (e.g., endo-
thelial cells). In this case, the agonistic Ab20 antibody may
have stimulated angiogenesis, as it is known that EA1-Fc
has stimulatory effects on endothelial cell migration in vitro
[33] and that ephrinA1 promotes angiogenesis in in vivo rat
corneal assays [34]. Further studies are needed to clarify
relative contributions to the tumor growth of ephrinA–EphA2
signaling activities from host and tumor cells.
An alternative explanation for the lack of efficacy of Ab20
is that oncogenic signaling pathways that are active in CT26
tumor cells are either more critical for in vivo tumor growth
than those involving EphA2, or enable tumor cells to escape
the inhibitory effects of an EphA2 agonist. In this regard, it is
of interest that ephrinA1 has been shown to inhibit growth
factor– induced—but not constitutively active—Ras/MAP
kinase activity in tumor cells [15,35]. If attenuation of MAP
kinase activity is important for the growth-inhibitory effects
of agonistic antibodies, the presence of activated Ras could
make cells resistant to that treatment. Given the frequent
occurrence of mutant activated Ras in human colorectal
cancers [36], it will be of interest to determine the status of
this pathway in CT26 cells.
Prior to initiating studies to evaluate the efficacy of Ab20
in other tumor types, we identified another EphA2 agonistic
mAb (1G9-H7) that is similar to EA1-Fc and Ab20 in the po-
tency and kinetics of EphA2 phosphorylation and degrada-
tion. However, unlike either of these agonists, 1G9-H7
specifically interacts with hEphA2 as demonstrated by its
binding (uniquely) to human cells that express EphA2 and its
competition with human—but not murine—EphA2 ECD.
1G9-H7 was tested for its ability to inhibit the growth of
orthotopically implanted MDA-231 breast tumors. The selec-
tion of this tumor model was influenced by the results
published by Coffman et al. [16], who showed that EphA2
agonistic antibodies inhibited MDA-MB-231 and A549 tumor
growth by 50% to 60% and also indicated that orthotopi-
cally implanted tumors were more responsive than subcuta-
neously growing tumors. In contrast to their observations,
treatment of MDA-231 tumors with the 1G9-H7 antibody
failed to affect tumor growth rate. Yet, all of the tumors ex-
cised from the 1G9-H7–treated mice had substantially lower
levels of EphA2 protein than the isotype-treated controls.
These data demonstrate that the 1G9-H7 antibody reached
the tumor and induced the degradation of EphA2, thereby
suggesting that high levels of EphA2 are not essential for
MDA-231 tumor growth. The reduction in EphA2 levels was
equal to or greater than that reported by investigators who
used anti-EphA2 siRNA or antibodies to decrease EphA2
levels in tumors [13,18]. In the MIAPaca-2 tumor study, the
administration of anti-EphA2 siRNA caused an approxi-
mately 70% inhibition of tumor growth, and the reduction of
EphA2 protein was approximately two-fold relative to con-
trols in the single sample shown [18]. In the MDA-MB-231
tumor study, anti-EphA2 EA2 antibody inhibited tumor
growth by f50%, and the levels of EphA2 in four of eight
tumors were undetectable although significant but un-
quantified levels were found in the remaining tumors [16].
It is possible that the MDA-231 cells that were used in our
study were not as dependent on EphA2 for their in vivo
growth as the cells used in the study by Coffman et al. [16],
further emphasizing the importance of determining the mo-
lecular characteristics of tumors that make them responsive
to anti-EphA2 therapies. Indeed, ephrinA1 treatment stimu-
lated the Ras–MAPK signaling pathway in the MDA-MB-231
cells studied by Pratt and Kinch [37] but had no effect on the
MDA-MB-231 cells employed by Mao et al. [35].
It is also conceivable that reduction of EphA2 protein
levels may not be the primary determinant of the growth-
inhibitory efficacy of EphA2-targeting therapies. Differences
in antibodies with respect to EphA2-binding affinity, agonistic
potency, site of interaction on the EphA2 protein, and down-
stream signal transduction may be more important for deter-
mining the antitumor efficacy of anti-EphA2 antibodies than
previously understood. The EC50 for the binding of 1G9-H7
to cell surface hEphA2 isf2 nM, which is comparable to the
reported binding affinity of the EA2 antibody (i.e., 5 nM) [16].
The kinetics of EphA2 degradation in MDA-MB-231 cells
induced by the EA2 antibody is also similar to that observed
with 1G9-H7. However, the EphA2-activating potency of the
EA2 antibody cannot be compared to that of 1G9-H7 be-
cause there were no direct comparisons made to EA1-Fc in
the published study. As the EphA2 phosphorylation studies
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with EA2 were performed at concentrations that were six-fold
greater than those required to achieve a maximal phosphory-
lation of EphA2 with 1G9-H7, it is possible that 1G9-H7 was
a more effective agonist than EA2. In this regard, it is note-
worthy that the EA2 antibody can bind to EphA2 by ELISA
measurement in the presence of EA1-Fc [16]. Thus, EA2
binds to a site on EphA2 that is different from that of the ligand
and still functions as an agonist. Our preliminary data indi-
cate that the 1G9-H7 antibody binds to an epitope that over-
laps with that of EA1-Fc. It is therefore possible that 1G9-H7
and EA2 may stimulate overlapping yet distinct signal trans-
duction pathways, in conjunction with EphA2 degradation,
thereby leading to different abilities to inhibit tumor growth.
Thus, induction of EphA2 degradation may not be the only
relevant outcome leading to the tumor growth-inhibitory abil-
ity of anti-EphA2 antibodies. Future studies to elucidate the
signaling pathways evoked by these antibodies will be im-
portant for determining the characteristics of EphA2-targeting
antibodies that have antitumor properties.
Finally, the specificity of the EA2 antibody toward hEphA2
is unknown. Cross-reactivity with other human or murine
ephrin receptors could also enhance the tumor growth–
inhibitory activity of this antibody.
In summary, we have generated and characterized two
potent agonistic mAbs directed against murine and human
EphA2. Following in vivo administration of these antibodies,
the levels of EphA2 protein in murine CT26 colorectal and
human MDA-231 breast tumors were reduced by at least
f80% to 85%, yet no effects on the growth of tumors in the
subcutaneous (CT26) or orthotopic (MDA-231) sites, or on
tumor cell colonization in the lung (CT26) were observed.
Our results indicate that the characteristics of agonistic anti-
EphA2 antibodies, in addition to EphA2-degrading ability,
may be critical determinants of antitumor activity. This study
also suggests that the molecular characterization of tumors
for markers that predict responsiveness to anti-EphA2 tar-
geting therapies is warranted.
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